Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient took three doses of Vivotif, and patient missed fourth dose; Case reference number US-BN-2025-001073 is a spontaneous case initially received from a nurse via agency (reference number: USBAV25-1420) on 16-Jun-2025 and concerns a 27-year-old, male patient. The patient's medical history and concomitant medication details were not provided. On unspecified dates (also reported as every other day from missing the dose on 15-Jun-2025) the patient received three doses of Vivotif (batch number: unknown) at an unknown dose, orally for typhoid prophylaxis. On 15-Jun-2025, the patient missed the fourth dose of Vivotif since had been abroad (explicitly coded as 'missed dose'). At the time of initial report, it was unknown if patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 27-year-old male patient missed the fourth dose of Vivotif since had been abroad, which is considered as missed dose. It was unknown if patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 27-year-old male patient missed the fourth dose of Vivotif since had been abroad, which is considered as missed dose. It was unknown if patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE